Cargando…

Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health

BACKGROUND: The clinical heterogeneity of the 22q11.2 Deletion Syndrome (22q11.2DS – OMIM, #188400 and #192430) is a universal challenge leading to diagnostic delay. The aim of this study was to evaluate a low cost strategy for the diagnosis of this condition based upon clinical criteria previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Sgardioli, Ilária Cristina, Paoli Monteiro, Fabíola, Fanti, Paulo, Paiva Vieira, Társis, Gil-da-Silva-Lopes, Vera Lúcia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547599/
https://www.ncbi.nlm.nih.gov/pubmed/31159889
http://dx.doi.org/10.1186/s13023-019-1098-1
_version_ 1783423715133882368
author Sgardioli, Ilária Cristina
Paoli Monteiro, Fabíola
Fanti, Paulo
Paiva Vieira, Társis
Gil-da-Silva-Lopes, Vera Lúcia
author_facet Sgardioli, Ilária Cristina
Paoli Monteiro, Fabíola
Fanti, Paulo
Paiva Vieira, Társis
Gil-da-Silva-Lopes, Vera Lúcia
author_sort Sgardioli, Ilária Cristina
collection PubMed
description BACKGROUND: The clinical heterogeneity of the 22q11.2 Deletion Syndrome (22q11.2DS – OMIM, #188400 and #192430) is a universal challenge leading to diagnostic delay. The aim of this study was to evaluate a low cost strategy for the diagnosis of this condition based upon clinical criteria previously reported. Health professionals, who collected clinical data, from twelve centers were trained in those criteria, which were summed through an online application (CranFlow). RESULTS: Clinical and laboratorial data of 347 individuals registered from 2008 to 2017 in the Brazilian Database on Craniofacial Anomalies/22q11.2 Deletion Syndrome, were reviewed. They were divided in two groups: (I) 168 individuals investigated before the definition of the criteria and (II) 179 individuals investigated after the criteria application. All of them were investigated for 22q11.2DS by Fluorescent in situ Hybridization (FISH) and/or Multiplex Ligation Probe-dependent Amplification (MLPA), detecting 98 cases with 22q11.2DS. Among the individuals with 22q11.2DS in Group II, 42/53 (79.25%) fulfilled the proposed criteria against 11/53 (20.75%) who did not fulfill them (p < .0001). The association of congenital heart diseases with high predictive value for 22q11.2DS and hypernasal voice were significantly associated to the presence of 22q11.2DS (p = 0.0172 and p < .0001, respectively). In addition, 22q11.2DS was confirmed 3.82 more times when the individuals fulfilled the proposed criteria. Of the 249 cases negative for the typical deletion in 22q11.2, Chromosomal Microarray Analysis (CMA) was performed in 132 individuals and detected pathogenic alterations at other genomic regions in 19 individuals, and variants of uncertain clinical significance in 31 cases. CONCLUSIONS: Therefore, a locus-specific approach could be used to individuals with positive criteria as a cost-effective alternative for 22q11.2DS diagnosis. The authors discuss advantages and suggest ways of implementing this approach to investigate 22q11.2DS in a public health system.
format Online
Article
Text
id pubmed-6547599
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65475992019-06-06 Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health Sgardioli, Ilária Cristina Paoli Monteiro, Fabíola Fanti, Paulo Paiva Vieira, Társis Gil-da-Silva-Lopes, Vera Lúcia Orphanet J Rare Dis Research BACKGROUND: The clinical heterogeneity of the 22q11.2 Deletion Syndrome (22q11.2DS – OMIM, #188400 and #192430) is a universal challenge leading to diagnostic delay. The aim of this study was to evaluate a low cost strategy for the diagnosis of this condition based upon clinical criteria previously reported. Health professionals, who collected clinical data, from twelve centers were trained in those criteria, which were summed through an online application (CranFlow). RESULTS: Clinical and laboratorial data of 347 individuals registered from 2008 to 2017 in the Brazilian Database on Craniofacial Anomalies/22q11.2 Deletion Syndrome, were reviewed. They were divided in two groups: (I) 168 individuals investigated before the definition of the criteria and (II) 179 individuals investigated after the criteria application. All of them were investigated for 22q11.2DS by Fluorescent in situ Hybridization (FISH) and/or Multiplex Ligation Probe-dependent Amplification (MLPA), detecting 98 cases with 22q11.2DS. Among the individuals with 22q11.2DS in Group II, 42/53 (79.25%) fulfilled the proposed criteria against 11/53 (20.75%) who did not fulfill them (p < .0001). The association of congenital heart diseases with high predictive value for 22q11.2DS and hypernasal voice were significantly associated to the presence of 22q11.2DS (p = 0.0172 and p < .0001, respectively). In addition, 22q11.2DS was confirmed 3.82 more times when the individuals fulfilled the proposed criteria. Of the 249 cases negative for the typical deletion in 22q11.2, Chromosomal Microarray Analysis (CMA) was performed in 132 individuals and detected pathogenic alterations at other genomic regions in 19 individuals, and variants of uncertain clinical significance in 31 cases. CONCLUSIONS: Therefore, a locus-specific approach could be used to individuals with positive criteria as a cost-effective alternative for 22q11.2DS diagnosis. The authors discuss advantages and suggest ways of implementing this approach to investigate 22q11.2DS in a public health system. BioMed Central 2019-06-03 /pmc/articles/PMC6547599/ /pubmed/31159889 http://dx.doi.org/10.1186/s13023-019-1098-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sgardioli, Ilária Cristina
Paoli Monteiro, Fabíola
Fanti, Paulo
Paiva Vieira, Társis
Gil-da-Silva-Lopes, Vera Lúcia
Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health
title Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health
title_full Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health
title_fullStr Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health
title_full_unstemmed Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health
title_short Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health
title_sort testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547599/
https://www.ncbi.nlm.nih.gov/pubmed/31159889
http://dx.doi.org/10.1186/s13023-019-1098-1
work_keys_str_mv AT sgardioliilariacristina testingcriteriafor22q112deletionsyndromepreliminaryresultsofalowcoststrategyforpublichealth
AT paolimonteirofabiola testingcriteriafor22q112deletionsyndromepreliminaryresultsofalowcoststrategyforpublichealth
AT fantipaulo testingcriteriafor22q112deletionsyndromepreliminaryresultsofalowcoststrategyforpublichealth
AT paivavieiratarsis testingcriteriafor22q112deletionsyndromepreliminaryresultsofalowcoststrategyforpublichealth
AT gildasilvalopesveralucia testingcriteriafor22q112deletionsyndromepreliminaryresultsofalowcoststrategyforpublichealth